The science behind what works.

In 1908, Ilya Metchnikoff received the Nobel Prize for his research on immune function. His observation that communities in Bulgaria who regularly consumed fermented milk were unusually healthy and long-lived led him to propose that lactic acid bacteria contribute directly to intestinal health. That hypothesis launched a century of research.

In Japan, Metchnikoff's work inspired physicians to import European yogurt cultures and develop bacterial intestinal regulators. When global conflict disrupted supply chains in the early twentieth century, Japanese researchers isolated beneficial bacteria domestically and developed them into regulated products — prescribed by physicians and sold in pharmacies, held to standards that had no equivalent in the Western supplement market.

This approach produced a class of product known as the seicho-zai, or intestinal regulator — clinically validated, strain-specific bacterial preparations with decades of safety data and regulatory oversight. They remain a cornerstone of Japanese healthcare today, available in every pharmacy across the country, trusted by physicians and consumers alike. One of these preparations, first developed in 1917, has maintained continuous clinical use for over a century.

Progurt's formulation descends directly from this tradition. Our strains were developed within the Japanese pharmaceutical research framework — isolated from healthy human sources, validated through clinical use, and held to exacting manufacturing standards. While the Western supplement industry was still debating whether probiotics worked at all, these strains had already accumulated decades of documented safety in clinical settings.

This is not a formulation assembled from commercially available starter cultures. It is the product of a lineage that predates the Western probiotic industry by generations.

The human large intestine contains an estimated 100 billion bacteria per gram of content. A typical commercial probiotic delivers between one and fifty billion colony-forming units per dose — a fraction of the bacterial population it's attempting to influence.

Progurt delivers one trillion CFU per sachet. The MEND Establish phase uses multiple sachets per day in a structured ramp, bringing the protocol dose to approximately seven trillion CFU on the first day of bacterial introduction alone.

This isn't an arbitrary number chosen for marketing impact. It reflects a principle demonstrated in published clinical research: the most dramatic outcomes in probiotic medicine have come from high-dose, multi-strain formulations at concentrations in the trillions. In a landmark randomised controlled trial, a high-dose multi-strain probiotic at 7.2 trillion CFU per day achieved a 42.9% remission rate in active ulcerative colitis, compared to 15.7% on placebo — a dose closely matched by Progurt's Establish protocol. In chronic pouchitis, 85% of patients on a high-dose probiotic at approximately three trillion bacteria per day maintained remission at nine months — compared to zero percent on placebo. An indirect meta-analytic comparison found that the same high-dose formulation was statistically indistinguishable from faecal microbiota transplantation in efficacy, with a comparable safety profile.

Dose-response research confirms the pattern even at conventional supplement levels. A randomised trial comparing 17.2 billion and 1.8 billion CFU of the same strain found dose-dependent improvements in gut transit time and gastrointestinal symptoms — with the higher dose producing significantly greater effects across nearly all measures. If higher outperforms lower within the billions, the clinical literature suggests that concentrations in the trillions produce the most dramatic outcomes. A meta-analysis of 33 randomised trials found that multi-strain formulations at higher doses had a greater beneficial effect on glycemic markers in type 2 diabetes than lower-dose or single-strain preparations.

Most probiotic products assume that swallowing bacteria is enough. It isn't. The gut environment — its pH, mineral content, barrier integrity, and motility — determines whether incoming bacteria survive, adhere, and establish colonies, or simply pass through without effect.

Published research demonstrates that this environment is critical. Zinc deficiency compromises intestinal barrier integrity and drives inflammatory immune responses. Magnesium supports gut motility and maintains the ion channels essential for epithelial function. When the gut lining is inflamed or permeable, beneficial bacteria cannot adhere to the intestinal wall effectively. When transit time is abnormal — too fast or too slow — probiotics don't have sufficient contact time to colonise.

A landmark 2018 study published in Cell provided direct evidence. Researchers at the Weizmann Institute administered a multi-strain probiotic to healthy volunteers, then performed endoscopies and colonoscopies to measure actual mucosal colonisation — not just stool detection. They found that the existing gut microbiome actively resisted probiotic colonisation, and that baseline gut composition predicted who would respond. Some people were "permissive" hosts; others were "resistant." The difference was not the probiotic — it was the environment receiving it. Only 30% of participants in a related trial achieved stable long-term engraftment of a probiotic strain, with success depending on whether the existing microbiome had an open ecological niche.

The companion study from the same group found that when antibiotics disrupted the gut ecosystem, probiotic colonisation actually increased — precisely because the environmental resistance had been removed. Notably, the same study found that this enhanced probiotic colonisation came at a cost: it delayed the reconstitution of the indigenous microbiome compared to spontaneous recovery. The existing microbiome is a gatekeeper. When it's intact and healthy, it resists newcomers. When it's disrupted, the gates are open — but what fills the gap, and in what order, matters profoundly.

This is why Progurt starts with minerals, not bacteria. Our pH sachets and chloride supplement prepare the intestinal environment — supporting hydration, buffering pH, restoring mineral balance, and creating the conditions under which beneficial bacteria can actually take hold. We call this the Terrain Model: fix the soil before you plant the seeds.

It's the step every other probiotic skips. And it's the reason most of them don't work.

Clinical microbiome restoration does not happen in a single step. When researchers perform faecal microbiota transplantation — the most direct form of microbiome intervention available — they follow a meticulous phased protocol. They prepare the recipient's gut environment first. They introduce the therapeutic bacteria second. They support the newly established ecosystem third. A large-scale clinical survey of over 600 transplant procedures found that the quality of gut preparation was one of the strongest predictors of treatment success — with insufficient preparation associated with a 5.5-fold increase in disease recurrence.

Progurt's MEND Method follows the same logic.

Every phase depends on the one before it. Skip Mineralise, and your bacteria land in hostile terrain. Rush Nourish before Establish, and you feed the wrong organisms. The sequence is not a marketing framework. It's a clinical logic supported by published microbiome research.

No published research has tested this exact four-phase sequence as a single protocol. What the literature does support — consistently, across multiple research groups and clinical contexts — is that phased microbiome restoration outperforms single-intervention approaches, that gut preparation determines probiotic success, and that prebiotic timing matters.